TORONTO, ON-Q BioMed Inc. reports that its research partner Mannin Research has been accepted into Johnson & Johnson Innovation, JLABS @ Toronto.
The two companies are partnering on the development of a pharmaceutical eye-drop to treat Primary Open-Angle Glaucoma utilizing the Tie2 Mechanism of Action. Q BioMed focuses on acquiring companies and biomedical assets, and providing these target companies and assets, strategic resources, developmental support and expansion capital.
JLABS @ Toronto is a 40,000 square-foot life science innovation center. The labs provide a flexible environment for start-up companies pursuing new technologies and research platforms to advance medical care. Through a “no strings attached” model, Johnson & Johnson Innovation does not take an equity stake in the companies occupying JLABS and the companies are free to develop products – either on their own, or by initiating a separate external partnership with Johnson & Johnson Innovation or any other company.
Mannin will utilize JLABS @ Toronto as complementary lab space to conduct commercial research and development as it relates to its MAN-01 program for Glaucoma and to the greater Tie2 platform technology. As a resident, Mannin will have access to the development and commercialization expertise provided by JLABS @ Toronto.